Journal Article

Risk of Guillain-Barré Syndrome following Serogroup C Meningococcal Conjugate Vaccine in Quebec, Canada

Philippe De Wals, Geneviève Deceuninck, Renée-Myriam Boucher and Manale Ouakki

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 46, issue 8, pages e75-e77
Published in print April 2008 | ISSN: 1058-4838
Published online April 2008 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1086/533469
Risk of Guillain-Barré Syndrome following Serogroup C Meningococcal Conjugate Vaccine in Quebec, Canada

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM197 conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.

Journal Article.  1562 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.